Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Gains from Investment Securities (2017 - 2026)

Denali Therapeutics has reported Gains from Investment Securities over the past 9 years, most recently at $1.3 million for Q4 2025.

  • Quarterly Gains from Investment Securities rose 206.62% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$49000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$49000.0 for FY2025, N/A changed from the prior year.
  • Gains from Investment Securities was $1.3 million for Q4 2025 at Denali Therapeutics, down from $1.7 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $2.9 million in Q1 2025 and troughed at -$5.9 million in Q2 2025.
  • The 5-year median for Gains from Investment Securities is $3000.0 (2021), against an average of $11357.1.
  • The largest YoY upside for Gains from Investment Securities was 29550.0% in 2024 against a maximum downside of 58800.0% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $210000.0 in 2021, then plummeted by 97.62% to $5000.0 in 2022, then crashed by 140.0% to -$2000.0 in 2023, then plummeted by 58800.0% to -$1.2 million in 2024, then soared by 206.62% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Gains from Investment Securities are $1.3 million (Q4 2025), $1.7 million (Q3 2025), and -$5.9 million (Q2 2025).